

# Alain Cohen-Solal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7686352/publications.pdf>

Version: 2024-02-01

65  
papers

3,181  
citations

236925

25  
h-index

161849

54  
g-index

65  
all docs

65  
docs citations

65  
times ranked

4017  
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2020, 26, 141-148.	1.8	388
2	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	364
3	Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study†. European Journal of Heart Failure, 2006, 8, 697-705.	7.1	286
4	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	234
5	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	184
6	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. European Journal of Heart Failure, 2017, 19, 1495-1503.	7.1	154
7	Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. European Journal of Heart Failure, 2017, 19, 201-208.	7.1	126
8	High prevalence of iron deficiency in patients with acute decompensated heart failure. European Journal of Heart Failure, 2014, 16, 984-991.	7.1	113
9	Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure. Journal of the American College of Cardiology, 2009, 53, 2343-2348.	2.8	107
10	Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014, 100, 1414-1420.	2.9	95
11	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	7.1	92
12	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. JACC: Heart Failure, 2015, 3, 629-636.	4.1	72
13	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure, 2020, 22, 1357-1365.	7.1	66
14	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. European Journal of Heart Failure, 2015, 17, 1114-1123.	7.1	49
15	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364.	2.2	47
16	2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine, 2020, 87, 395-404.	1.6	47
17	Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome. ESC Heart Failure, 2020, 7, 4371-4376.	3.1	46
18	Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. International Journal of Cardiology, 2015, 199, 241-247.	1.7	44

#	ARTICLE	IF	CITATIONS
19	Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure, 2017, 4, 499-506.	3.1	42
20	The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. JACC: Heart Failure, 2021, 9, 169-178.	4.1	39
21	Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. Journal of Nuclear Medicine, 2005, 46, 1796-803.	5.0	36
22	Recent advances in cardio-oncology: a report from the Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019™. ESC Heart Failure, 2019, 6, 1140-1148.	3.1	34
23	Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. Archives of Cardiovascular Diseases, 2015, 108, 64-74.	1.6	32
24	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	7.1	32
25	Management of acute heart failure in elderly patients. Archives of Cardiovascular Diseases, 2016, 109, 422-430.	1.6	28
26	Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists. Archives of Cardiovascular Diseases, 2014, 107, 563-571.	1.6	27
27	Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Failure, 2022, 9, 11-20.	3.1	27
28	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 231-239.	7.1	26
29	Management of Immune Checkpoint Inhibitor-Induced Myocarditis. JACC: CardioOncology, 2021, 3, 157-161.	4.0	22
30	Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Failure, 2022, 9, 874-884.	3.1	22
31	Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. European Journal of Preventive Cardiology, 2021, 28, 541-557.	1.8	20
32	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. International Journal of Cardiology, 2021, 327, 138-145.	1.7	19
33	Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 83-91.	7.1	17
34	2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. Joint Bone Spine, 2020, 87, 387-393.	1.6	17
35	Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action. Journal of Internal Medicine, 2022, 292, 542-556.	6.0	17
36	Effects of Cardiopulmonary Exercise Rehabilitation on Left Ventricular Mechanical Efficiency and Ventricular-Arterial Coupling in Patients With Systolic Heart Failure. Journal of the American Heart Association, 2015, 4, e002084.	3.7	16

#	ARTICLE	IF	CITATIONS
37	Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Failure, 2021, 8, 1509-1521.	3.1	14
38	East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. European Journal of Heart Failure, 2018, 20, 1071-1075.	7.1	13
39	Left Atrioventricular Coupling Index to Predict Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2021, 8, 704611.	2.4	13
40	Non-vitamin K antagonist oral anticoagulants and heart failure. Archives of Cardiovascular Diseases, 2016, 109, 641-650.	1.6	12
41	Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol. ESC Heart Failure, 2021, 8, 928-937.	3.1	11
42	Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. Nutrients, 2022, 14, 1039.	4.1	11
43	Natriuretic peptides in addition to Zwolle score to enhance safe and early discharge after acute myocardial infarction: A prospective observational cohort study. International Journal of Cardiology, 2016, 215, 527-531.	1.7	10
44	RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research. European Journal of Heart Failure, 2017, 19, 1355-1357.	7.1	9
45	Baseline subendocardial viability ratio influences left ventricular systolic improvement with cardiac rehabilitation. Anatolian Journal of Cardiology, 2017, 17, 37-43.	0.9	9
46	Assessment of dyspnoea in the emergency department by numeric and visual scales: A pilot study. Anaesthesia, Critical Care & Pain Medicine, 2015, 34, 95-99.	1.4	8
47	Association between baseline cardiovascular mechanics and exercise capacity in patients with coronary artery disease. Anatolian Journal of Cardiology, 2015, 16, 608-613.	0.9	8
48	Right ventricular function and iron deficiency in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 406-414.	1.0	8
49	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
50	The value of novel invasive hemodynamic parameters added to the TIMI risk score for short-term prognosis assessment in patients with ST segment elevation myocardial infarction. International Journal of Cardiology, 2016, 214, 235-240.	1.7	6
51	Characterization of non-response to cardiac resynchronization therapy by post-procedural computed tomography. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 135-144.	1.2	6
52	Education and certification on heart failure of the Heart Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 249-253.	7.1	6
53	Ambulatory cardiac rehabilitation facilities should be present in every cardiology department. European Journal of Preventive Cardiology, 2018, 25, 1704-1706.	1.8	5
54	Recommandations de la Soci�t� fran�saise de rhumatologie pour la prise en charge de la goutte: le traitement hypo-uric�miant. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 332-341.	0.0	5

#	ARTICLE	IF	CITATIONS
55	Iron deficiency in pulmonary arterial hypertension: perspectives. <i>Pulmonary Circulation</i> , 2021, 11, 1-4.	1.7	5
56	Coronary Computed Tomography Angiography Analysis of Calcium Content to Identify Non-culprit Vulnerable Plaques in Patients With Acute Coronary Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 876730.	2.4	5
57	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2976.	2.4	5
58	Effects of Physical Exercise on Cardiovascular Diseases: Biochemical, Cellular, and Organ Effects. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	4
59	Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. <i>Archives of Gerontology and Geriatrics</i> , 2017, 68, 33-38.	3.0	4
60	Iron deficiency in heart failure: why so frequent and which mechanisms?. <i>European Heart Journal</i> , 2022, 43, e35-e37.	2.2	3
61	Effects of exercise on postexercise ventricular-arterial coupling and pulsatile efficiency in patients with systolic dysfunction. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1042-1051.	3.4	2
62	Is the glass half full or half empty after PARAGON-HF?. <i>Cardiovascular Research</i> , 2020, 116, e5-e7.	3.8	2
63	Severe Myocardial Dysfunction after Non-Ischemic Cardiac Arrest: Effectiveness of Percutaneous Assist Devices. <i>Journal of Clinical Medicine</i> , 2021, 10, 3623.	2.4	1
64	Could Nephilysin Be Already Inhibited by BNP in the LIFE Trial?. <i>JAMA Cardiology</i> , 2022, , .	6.1	1
65	All rise! Orthostatic hypotension in heart failure: reply. <i>European Journal of Heart Failure</i> , 2020, 22, 1742-1742.	7.1	0